Literature DB >> 4033300

Effects of dantrolene sodium on occlusion and reperfusion arrhythmias in the canine heart.

A Pelleg, A Roth, B Shargordsky, B Belhassen, A Chagnac, S Laniado.   

Abstract

The effects of dantrolene sodium on occlusion and reperfusion ventricular arrhythmias (VA) were studied in a canine model. Transient ischemia was induced by a 10 min occlusion period of the left anterior descending coronary artery in 27 control dogs and 32 dogs pretreated with dantrolene sodium (2.5 mg/kg). In the control group, 14 (52%) dogs experienced VA during occlusion. Five of these had ventricular fibrillation, 3 of which were fatal. Eight of 24 control dogs which reached reperfusion experienced ventricular fibrillation during the first 30 sec of reperfusion. Dantrolene sodium did not lower the frequency of VA during occlusion 22/32 (69%). Moreover, the incidence of fatal ventricular fibrillation during occlusion was significantly (p less than 0.025) higher in the drug treated-group (12/32; 37.5%) than in the control group (3/27; 11%). Dantrolene sodium also significantly reduced the time that lasted from the commencement of occlusion to the appearance of ventricular fibrillation (240 +/- 1 sec versus 166 +/- 9 seconds, control and drug group, respectively p less than 0.05) without significantly altering either heart rate or blood pressure (169 +/- 4 b.p.m., and 170 +/- b.p.m.; 101 +/- 10 mmHg and 104 +/- 9 mmHg, before and after dantrolene sodium, respectively). These results indicate that dantrolene sodium might have an arrhythmogenic effect in the ischemic canine heart.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4033300

Source DB:  PubMed          Journal:  Methods Find Exp Clin Pharmacol        ISSN: 0379-0355


  5 in total

1.  Dantrolene: from better bacon to a treatment for ventricular fibrillation.

Authors:  Dan M Roden; Björn C Knollmann
Journal:  Circulation       Date:  2014-01-08       Impact factor: 29.690

Review 2.  Targeting ryanodine receptors for anti-arrhythmic therapy.

Authors:  Mark D McCauley; Xander H T Wehrens
Journal:  Acta Pharmacol Sin       Date:  2011-06       Impact factor: 6.150

3.  Cardiac implications of amlodipine-dantrolene combinations.

Authors:  M Freysz; Q Timour; C Bernaud; L Bertrix; G Faucon
Journal:  Can J Anaesth       Date:  1996-01       Impact factor: 5.063

Review 4.  Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity.

Authors:  A Ward; M O Chaffman; E M Sorkin
Journal:  Drugs       Date:  1986-08       Impact factor: 9.546

5.  Effects of dantrolene on arrhythmogenicity in isolated regional ischemia-reperfusion rabbit hearts with or without pacing-induced heart failure.

Authors:  Chung-Chuan Chou; Hui-Ling Lee; Po-Cheng Chang; Hung-Ta Wo; Ming-Shien Wen; San-Jou Yeh
Journal:  Biomed Res Int       Date:  2015-02-19       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.